Can a blood protein predict better diabetes treatment?
NCT ID NCT07539584
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study in 130 adults with type 2 diabetes and fatty liver disease tested whether a blood marker called adiponectin can predict how well certain diabetes drugs reduce liver fat. Participants received either an SGLT2 inhibitor, a GLP-1 receptor agonist, or both for six months. The goal was to see if changes in adiponectin levels matched improvements in liver health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SGLT2 inhibitors (dapagliflozin or empagliflozin) and GLP-1 receptor agonists
What this could lead to
If successful, this could help doctors predict which diabetes medications best reduce liver fat in patients with fatty liver disease.
What could go wrong
This is a small, completed study focused on a biomarker, not a treatment outcome. Results may not lead to new therapies or apply to broader populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS (T2DM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moscow Regional Research and Clinical Institute
Moscow, 129110, Russia